Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1.

Lung cancer is still the leading cause of cancer-related deaths worldwide. Identifying new oncogenic drivers and developing efficient inhibitors through molecular targeting approaches are crucial for improving therapies. The aim of this study was to investigate whether targeting fibroblast growth factor receptor 1 (FGFR1) with ponatinib inhibits the cell growth in both established and primary lung cancer cells overexpressing FGFR1. Eighty-eight non-small cell lung cancer (NSCLC) and paired normal tissue specimens were analyzed by real-time RT-PCR for FGFR1 gene expression. We identified four cell lines and two newly established primary lung cancer cultures that showed high FGFR1 expression levels, and evaluated the effect of the novel FGFR1 inhibitor ponatinib on cell growth. Approximately 50% (30 out of 59) NSCLC specimens expressed FGFR1>2-fold compared with their adjacent normal counterparts using quantitative RT-PCR. Ponatinib treatment of established NSCLC cell lines expressing higher levels of FGFR1 resulted in marked cell growth inhibition and suppression of clonogenicity. This growth inhibition was associated with inactivation of FGFR1 and its downstream targets. FGFR1 knockdown by shRNA achieved similar results when compared to treatment with ponatinib. Furthermore, ponatinib was able to significantly inhibit the growth of primary lung cancer cultures in vitro. Our data indicate that pharmacological inhibition of FGFR1 kinase activity with ponatinib may be effective for the treatment of lung cancer patients whose tumors overexpress FGFR1.

[1]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[2]  M. Meyerson,et al.  Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer , 2011, PloS one.

[3]  T. Clackson,et al.  Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models , 2012, Molecular Cancer Therapeutics.

[4]  J. Cowell,et al.  Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease. , 2011, Blood.

[5]  R. Salgia,et al.  MET pathway as a therapeutic target. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Elisabeth Brambilla,et al.  Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities , 2012, Clinical Cancer Research.

[7]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[8]  H. Sasaki,et al.  Increased FGFR1 copy number in lung squamous cell carcinomas. , 2011, Molecular medicine reports.

[9]  L. Tanoue,et al.  Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .

[10]  T. Clackson,et al.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.

[11]  Y. Samuels,et al.  Oncogenic mutations of PIK3CA in human cancers. , 2004, Current topics in microbiology and immunology.

[12]  R. Govindan,et al.  Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010). , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  J. Cowell,et al.  Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities , 2012, Leukemia.

[14]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[15]  M. Ittmann,et al.  Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. , 2003, Cancer research.

[16]  R. Govindan,et al.  Annual Review of Advances in Lung Cancer Clinical Research: A Report for the Year 2009 , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  M. Meyerson,et al.  ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[19]  Mustafa Ozen,et al.  Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. , 2003, Cancer research.

[20]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[21]  P. Bunn,et al.  Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells , 2009, Molecular Pharmacology.

[22]  J. Mate,et al.  Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. , 1993, Oncogene.

[23]  Y. Qi,et al.  Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate , 2010, Breast Cancer Research and Treatment.

[24]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[25]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[26]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[27]  J. Subramanian,et al.  Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) Focus on Tumor Biology and Biomarkers Related to Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  A. Ashworth,et al.  FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.

[29]  M. Stratton.  Exploring the Genomes of Cancer Cells: Progress and Promise , 2011, Science.

[30]  Andrew Chase,et al.  Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome , 2013, Haematologica.

[31]  Xiurong Li,et al.  Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. , 2009, Blood.

[32]  A. Tsao,et al.  ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .

[33]  R. Lotan,et al.  Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer , 2008, Clinical Cancer Research.

[34]  A. Ashworth,et al.  Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.

[35]  John K Heath,et al.  Src kinase modulates the activation, transport and signalling dynamics of fibroblast growth factor receptors , 2007, EMBO reports.

[36]  J. Cowell,et al.  The temporal and spatial expression pattern of the LGI1 epilepsy predisposition gene during mouse embryonic cranial development , 2011, BMC Neuroscience.

[37]  J. Fridlyand,et al.  Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis , 2009, Oncogene.

[38]  J. Cowell,et al.  Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases. , 2011, Cancer research.

[39]  R. V. van Etten,et al.  Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. , 2004, Cancer cell.

[40]  Trista K. Hinz,et al.  Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression , 2010, PloS one.

[41]  G. Amann,et al.  Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. , 2006, American journal of clinical pathology.

[42]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[43]  Z. Darżynkiewicz,et al.  Analysis of DNA Content and BrdU Incorporation , 1997, Current protocols in cytometry.

[44]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[45]  H. Larsson,et al.  Fibroblast Growth Factor Receptor-1-mediated Endothelial Cell Proliferation Is Dependent on the Src Homology (SH) 2/SH3 Domain-containing Adaptor Protein Crk* , 1999, The Journal of Biological Chemistry.